Can CD200 Biomarker Predict Multiple Myeloma Outcomes?

An immune checkpoint molecule called CD200 might be an important marker in cancer. Traditionally, this molecule prevents the immune system from attacking its own tissues. However, in many cancers, CD200 is "hijacked" to help tumors hide from the immune system.

Recent research, including a comprehensive review in Biomedicines, reveals that CD200 has a two-way role. This means it can either promote or inhibit cancer, depending on the type of tumor and its surroundings.

What is the CD200 Pathway?

CD200 is a protein found on the surface of various cells. It primarily functions by binding to its partner, a receptor called CD200R, which is often found on immune cells within a tumor.

Researchers have discovered two ways this molecule communicates with cells: 

• CD200 communicates with cells by binding to CD200R. Then it sends a signal that tells immune cells to "stand down". This lowers the activity of the immune system's natural defense against cancer cells and microorganisms.
• In a more recent discovery, a piece of the CD200 protein actually breaks off and travels into the cell's nucleus. Once there, it can directly turn on genes that help cancer cells grow and spread.

When does CD200 promote cancer growth?

High levels of CD200 are associated with poorer outcomes in myeloma. It facilitates cancer progression through several mechanisms:

• Disarming "Natural Killer" (NK) Cells.
• Exhausting T cells.
• Recruiting regulatory T cells and myeloid-derived suppressor cells. These cells act like a shield, preventing other immune cells from eliminating the cancer.

High levels of CD200 have been linked to the "Epithelial-to-Mesenchymal Transition" (EMT). This is a process where cancer cells gain the ability to migrate and invade other parts of the body.

CD200 in multiple myeloma 

A recent study analyzed the clinical impact of CD200. This study included 291 patients with newly diagnosed myeloma. It found a link between CD200 expression and lower overall survival (OS). Patients with this specific genotype had a median OS of 67.8 months, compared to 94.4 months for those with other genotypes.

The study also found that people with high CD200 expression had more risk if they didn’t undergo a stem cell transplant. And CD200 was associated with higher mortality, largely due to an increased incidence of infection events. 

Interestingly, the genotype did not correlate with the time to progression or progression-free survival, suggesting it may primarily reflect an inadequate immune response rather than a mechanism of cancer cell escape. 

These findings indicate that the CD200 genotype could serve as a valuable genetic marker to identify high-risk patients who could benefit from stricter infection monitoring and personalized immune-based therapies.

Can CD200 be helpful? 

In some cancers like breast cancer and melanoma, CD200 has shown anti-tumor effects. In breast cancer it may limit tissue inflammation and reduce the production of certain proteins that help cancer spread. And in melanoma it helps recruit more active T cells into the tumor and prevent the formation of new blood vessels in cancer tissue.

Blocking CD200 may become one useful strategy for newer treatments

Because CD200 often acts as a brake on the immune system, scientists are testing medicines that can release that brake.

• Samalizumab: This is a humanized antibody used in a Phase I clinical trial for patients with chronic lymphocytic leukemia (CLL) and multiple myeloma. In the trial, it helped restore immune activity and reduced the tumor burden in several patients.
• Combination therapies: Researchers are looking at using CD200 blockers alongside other treatments, like PD-1/PD-L1 inhibitors (such as Nivolumab), to see if they can work together to more effectively kill cancer cells.

The CD200 is a complex part of cancer biology. While it often helps cancer cells evade the immune system, its role varies depending on the specific cancer type and the patient's individual "cancer microenvironment". Continued clinical trials are essential to determine which patients will benefit most from targeting this pathway.

Read more news like this and stay tuned for our community events and programs with the HealthTree newsletter.

SUBSCRIBE TO NEWSLETTER

Sources: 

• CD200 genotype is associated with clinical outcome of patients with multiple myeloma
• CD200/CD200R: Bidirectional Role in Cancer Progression and Immunotherapy
• CD200-CD200R signaling suppresses anti-tumor responses independently of CD200 expression on the tumor
• Clinical significance of CD200 expression in newly diagnosed multiple myeloma patients and dynamic changing during treatment